Trial Profile
Pilot Study Evaluating Maraviroc (Celsentri)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Biomarker; Therapeutic Use
- Acronyms MARIMUNO
- 25 Feb 2016 Results (n=22) presented at the 23rd Conference on Retroviruses and Opportunistic Infections
- 10 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 10 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.